toxicology-congress-2017-scientifictracks-abstracts

14 / 33

Page 46
Notes:
conferenceseries.com
Volume 3, Issue 1 (Suppl) Toxicol Open Access
ISSN: 2476-2067 TYOA, an open access journal Toxicology Congress 2017
April 13-15, 2017
April 13-15, 2017 Dubai, UAE
8th World Congress on
Toxicology and Pharmacology
The role of endothelial biomarkers in breast cancer metastasis
Maria Walczak
Jagiellonian University, Poland
Statement of the Problem: Metastatic cancers are the main cause of cancer-related death in the world. For this reason
identification of novel treatment targets is warranted. Study of breast cancer metastasis is limited due to poor knowledge in
progression of breast tumor and varied heterogeneity. Breast cancer metastasis is a complicated process in which each step
is modulated by a complex network of signaling pathways. In recent years attention is paid to the significance of vascular
endothelium in cancer metastasis and abundant evidence suggests that endothelial inflammation plays an important
pathogenetic role in the development of metastasis. The purpose of this study was to describe changes in endothelium in
mouse model of 4T1 metastatic breast cancer at various stages of disease progression with the use of the multi-protein panel
of endothelial biomarkers.
Methodology & Theoretical Orientation: The panel contains proteins of glycocalyx disruption: syndecan-1 (SDC-1) and
endocan (ESM-1); pro-inflammatory molecules: soluble intercellular adhesion molecule 1 (sICAM-1), soluble vascular cell
adhesion molecule 1 (sVCAM-1) and soluble form of E-selectin (sE-sel); pro-thrombotic molecule: von Willebrand factor
(vWF); fibrinolyticmolecules: plasminogenactivator inhibitor 1 (PAI-1) and tissueplasminogenactivator (t-PA); pro-angiogenic
molecules: the soluble form of the fms-like tyrosine kinase 1 (sFlt-1), angiopoietin 2 (Angpt-2) and adrenomedullin (ADM),
and protein secreted by adipocytes - adiponectin (ADN). The biomarkers were determined using the liquid chromatography/
mass spectrometry-multiple reaction monitoring-based method (LC/MS-MRM).
Findings:Some of these proteins altered during breast cancer progression.
Using a panel of selected molecules was enabled to identify endothelial
biomarkers for early and late metastatic phase.
Conclusion & Significance: Endothelial dysfunction in cancer confirms
the hypothesis that condition of endothelium is a key step for disease
development. The simultaneous analysis of many biomarkers in one
sample enables for multidimensional screening of endothelial function in
mouse 4T1 breast cancer.
Biography
Maria Walczak has graduated from the Faculty of Pharmacy, Medical Academy in Krakow. She has obtained her PhD degree from the Faculty of Pharmacy,
Jagiellonian University Medical College (UJ CM), Krakow in 2001 and habilitation thesis in Pharmacokinetics in 2014. Since 2001, she worked at the Department
of Pharmacokinetics and Physical Pharmacy UJ CM as a Lecturer, since 2010 at the Jagiellonian Centre for Experimental Therapeutics (JCET) as a Manager of
the Laboratory of Analytics and Pharmacokinetics, and since 2015 as a Head of Chair at Department of Toxicology, Faculty of Pharmacy UJ CM. Her scientific
work refers to pharmacokinetic and toxicokinetic profiling, metabolite screening, assessment of protein binding of bioactive compounds and pharmacology of
endothelium. She is keen in bioanalysis of novel compounds and biomarkers related to cancer metastasis using LC/MS/MS and CE techniques. She is a specialist
in clinical pharmacy issues.
Maria Walczak, Toxicol Open Access 2017, 3:1 (Suppl)